Warby Parker (Warby Parker) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Warby Parker Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Warby Parker is: No Data: Cannot be evaluated.

Competitive Comparison of Warby Parker's Risk Assessment

For the Medical Instruments & Supplies subindustry, Warby Parker's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Warby Parker's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Warby Parker's Risk Assessment falls into.

Warby Parker (NYSE:WRBY) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Warby Parker Risk Assessment Related Terms

Thank you for viewing the detailed overview of Warby Parker's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Warby Parker (Warby Parker) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Warby Parker Inc (NYSE:WRBY) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Spring Street, 6th Floor East, New York, NY, USA, 10013

Website

https://www.warbyparker.com

Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts to eye exams and vision tests. Brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company primarily derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Executives

Steven Clive Miller	officer: Chief Financial Officer	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
David Abraham Gilboa	director, officer: Co-Chief Executive Officer	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Neil Harris Blumenthal	director, officer: Co-Chief Executive Officer	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Durable Capital Partners Lp	10 percent owner	4747 BETHESDA AVENUE, SUITE #1002, BETHESDA MD 20814
Teresa Briggs	director	2225 LAWSON LANE, SANTA CLARA CA 95054
Ronald A Williams	director
Jeffrey Jacob Raider	director	C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Andrew Hunt	director	C/O ELEPHANT PARTNERS, 11 NEWBURY STREET, 5TH FLOOR, BOSTON MA 02116
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Joel E Cutler	director, 10 percent owner	C/O GENERAL CATALYST PARTNERS, 20 UNIVERSITY ROAD, SUITE 450, CAMBRIDGE MA 02138
Youngme E Moon	director	75 NETWORK DRIVE, BURLINGTON MA 01803
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
General Catalyst Group V Lp	10 percent owner	c/o General Catalyst Group Management LL, 20 University Road Ste 450, Cambridge MA 02138
Gabrielle Sulzberger	director	450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017
General Catalyst Group Management Holdings, L.p.	10 percent owner	20 UNIVERSITY ROAD, 4TH FLOOR, CAMBRIDGE MA 02138